IL309085A - Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis - Google Patents

Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Info

Publication number
IL309085A
IL309085A IL309085A IL30908523A IL309085A IL 309085 A IL309085 A IL 309085A IL 309085 A IL309085 A IL 309085A IL 30908523 A IL30908523 A IL 30908523A IL 309085 A IL309085 A IL 309085A
Authority
IL
Israel
Prior art keywords
osteoarthritis
treatment
dosing regimen
nlrp3 inhibitor
nlrp3
Prior art date
Application number
IL309085A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL309085A publication Critical patent/IL309085A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL309085A 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis IL309085A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163224890P 2021-07-23 2021-07-23
PCT/IB2022/056695 WO2023002399A1 (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
IL309085A true IL309085A (en) 2024-02-01

Family

ID=82846336

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309085A IL309085A (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Country Status (8)

Country Link
US (1) US20250082611A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373489A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525897A (cg-RX-API-DMAC7.html)
KR (1) KR20240038995A (cg-RX-API-DMAC7.html)
CN (1) CN117693340A (cg-RX-API-DMAC7.html)
CA (1) CA3224774A1 (cg-RX-API-DMAC7.html)
IL (1) IL309085A (cg-RX-API-DMAC7.html)
WO (1) WO2023002399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
JP2021529780A (ja) * 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment

Also Published As

Publication number Publication date
JP2024525897A (ja) 2024-07-12
CN117693340A (zh) 2024-03-12
KR20240038995A (ko) 2024-03-26
EP4373489A1 (en) 2024-05-29
US20250082611A1 (en) 2025-03-13
WO2023002399A1 (en) 2023-01-26
CA3224774A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
IL311840A (en) Ras inhibitors
IL314033A (en) Ras inhibitors
DK4337652T3 (da) NLRP3-hæmmere
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
DK4363406T3 (da) Nlrp3-inflammasomhæmmere
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
IL290845A (en) Kras g12d inhibitors
IL315027A (en) Inhibitors of nlrp3
EP4192585A4 (en) Kras g12d inhibitors
EP4240489A4 (en) KRAS-G12D INHIBITORS
EP4182313A4 (en) KRAS-G12D INHIBITORS
EP4216951A4 (en) KRAS G12D INHIBITORS
IL287042A (en) Inflammatory inhibitors of nlrp3
EP4262803A4 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
IL284492B (en) Beam information in early measurements
IL283106A (en) Erk inhibitors and uses thereof
LT3661921T (lt) Selektyvūs nlrp3 inflamasomos inhibitoriai
EA201691421A1 (ru) Гетероарилы и их применение
EP3761992A4 (en) ARGINASE INHIBITORS
LT3405495T (lt) Inhibitorių kelių neutralizavimas limfocituose
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
IL280770A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3370064A4 (en) REAGENT AND METHOD FOR MEASURING A THROMBIN ANTITHROMBIN COMPLEX